Rosetta Genomics Reports Study Comparing microRNA Profiles of Cancer of Unknown Primary and Metastases of Known Primary Tumors

January 9, 2013

PHILADELPHIA and REHOVOT, Israel, Jan. 9, 2013 /PRNewswire/ — Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that data from a study assessing the differences between cancer of unknown primary (CUP) and metastatic solid tumors of known primary metastases (KPM) by profiling microRNA expression were recently published [...]

Read the full article →

Degradome Sequencing Workshop

January 8, 2013

Workshop – Degradome Sequencing / Plant RNA Extraction Methods Presented at the Plant & Animal Genomes Conference XXI Date: Monday, January 14, 2013 Time: 6:10 PM-8:20 PM Room: Pacific Salon 1 This workshop will provide an overview of the degradome sequencing method for miRNA target identification, as well as practical information for performing degradome sequencing [...]

Read the full article →

Santaris Pharma A/S and miRagen Therapeutics Inc. expand worldwide strategic alliance to discover and develop LNA-drugs against disease causing microRNAs

January 8, 2013

HOERSHOLM, Denmark and BOULDER, Colo., Jan. 8, 2013 /PRNewswire/ — Santaris Pharma A/S and miRagen Therapeutics, Inc. today announced that they have expanded their existing partnership in the field of microRNA therapeutics. Under the expanded agreement, miRagen obtains a broad non-exclusive license in the miRNA therapeutics field for therapeutics research and world-wide exclusive rights to research, [...]

Read the full article →

ChIPBase: decoding the transcriptional regulation of microRNA and lncRNA genes from ChIP-Seq data

November 28, 2012

microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) and represent two classes of important non-coding RNAs in eukaryotes. Although these non-coding RNAs have been implicated in organismal development and in various human diseases, surprisingly little is known about their transcriptional regulation. Recent advances in chromatin immunoprecipitation with next-generation DNA sequencing (ChIP-Seq) have provided methods of detecting [...]

Read the full article →

Announcing the 9th Annual “microRNA: Targets and Tools for Therapeutic Development” Conference

November 28, 2012

Cambridge Healthtech Institute announces the 9th Annual MicroRNA Targets and Tools for Therapeutic Development Conference on March 4th and 5th, 2013 at the Boston Marriott in Cambridge, MA. Registration is now open and there is an early registration discount until December 7th, 2012, while the advanced registration deadline is January 25th, 2013. Poster abstracts are [...]

Read the full article →

MicroRNAs in plants: Regulation of the regulator

November 8, 2012

A phosphate switch to fine-tune the protein production in the cells: Fast-Forward Genetics Identifies Plant CPL Phosphatases as Regulators of miRNA Processing Factor HYL1   MicroRNAs are essential regulators of the genetic program in multicellular organisms. Because of their potent effects, the production of these small regulators has itself to be tightly controlled. That is [...]

Read the full article →

miRview® lung – Final Approval for Rosetta Genomics’ microRNA Diagnostic Allows Identification of Four Major Subtypes of Lung Cancer

November 6, 2012

New, Targeted Therapies Make Accurate Classification of Lung Cancer Increasingly Important PHILADELPHIA and REHOVOT, Israel, Nov. 6, 2012 /PRNewswire/ – Rosetta Genomics (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic assays, announces that the New York State Department of Health has given the Company final approval for its miRview® lung assay following conditional [...]

Read the full article →

Regulus Announces $80.9 Million in Total Gross Proceeds from IPO and Other Recent Financial Transactions

November 5, 2012

LA JOLLA, Calif., Nov. 5, 2012 /PRNewswire/ – Regulus Therapeutics Inc. ( NASDAQ : RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, summarized today its recent financing activity that the company expects will enable Regulus to execute its current strategic objectives for the foreseeable future. In connection with Regulus’ Initial [...]

Read the full article →

Call for Papers: MiRNAs and Thyroid Cancer

October 31, 2012

The International Journal of Endocrinology is looking for contributions in the field of miRNAs & thyroid cancer. Both, original research articles as well as review articles that explore the influence of microRNAs in the development and progression of thyroid tumors will be considered. In addition, the editors are interested in articles that attempt to define [...]

Read the full article →

The Role of MicroRNA ‘Sponges’

October 30, 2012

The research and field of microRNA (miRNA) is relatively young in molecular biology. Researchers are only beginning to ascertain the essential functional impact that miRNA serve in tissue development and disease progression. For example, miRNA can act as both oncogenic ‘oncomirs’ or as tumor-suppressor genes in cancer biology. Amazingly, those same miRNA genes can also [...]

Read the full article →

← Previous Entries

Next Entries →